Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedFeb 24, 2026
DataAggregated Company Financials
Companies7
  • 7D-2.9%
  • 3M-1.2%
  • 1Y-12.6%
  • YTD-2.1%

Over the last 7 days, the Life Sciences industry has risen 1.3%, driven by gains from Tecan Group of 2.7%. During this same period, the Bachem Holding underperformed, falling 12%. However, the industry is down 8.8% over the past year. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 24 Feb 2026CHF 48.0bCHF 10.1bCHF 1.3b29.1x37.2x4.7x
Thu, 22 Jan 2026CHF 52.5bCHF 10.6bCHF 1.1b33.9x47.8x4.9x
Sat, 20 Dec 2025CHF 48.6bCHF 10.6bCHF 1.1b28.7x44.2x4.6x
Mon, 17 Nov 2025CHF 49.1bCHF 10.6bCHF 1.1b28.3x44.6x4.6x
Wed, 15 Oct 2025CHF 48.2bCHF 10.6bCHF 1.1b29.6x43.9x4.5x
Fri, 12 Sep 2025CHF 51.9bCHF 10.6bCHF 1.1b32.9x47.1x4.9x
Sun, 10 Aug 2025CHF 51.6bCHF 10.7bCHF 1.1b33.4x44.9x4.8x
Tue, 08 Jul 2025CHF 52.0bCHF 10.1bCHF 1.0b32.7x50x5.2x
Thu, 05 Jun 2025CHF 52.1bCHF 10.1bCHF 1.0b30.8x50.1x5.2x
Sat, 03 May 2025CHF 55.0bCHF 10.1bCHF 1.0b31.5x52.9x5.5x
Mon, 31 Mar 2025CHF 53.1bCHF 10.1bCHF 1.0b33.1x51.8x5.3x
Wed, 26 Feb 2025CHF 55.4bCHF 10.1bCHF 1.0b32.5x53.4x5.5x
Fri, 24 Jan 2025CHF 56.5bCHF 10.2bCHF 943.2m35.9x59.9x5.5x
Sun, 22 Dec 2024CHF 52.2bCHF 10.2bCHF 943.6m35.2x55.3x5.1x
Tue, 19 Nov 2024CHF 51.8bCHF 10.2bCHF 943.5m40.9x54.9x5.1x
Thu, 17 Oct 2024CHF 54.4bCHF 10.2bCHF 943.4m41.3x57.7x5.3x
Sat, 14 Sep 2024CHF 57.5bCHF 10.2bCHF 937.0m44.5x61.3x5.6x
Mon, 12 Aug 2024CHF 57.4bCHF 10.2bCHF 924.0m45.2x62.2x5.6x
Wed, 10 Jul 2024CHF 54.0bCHF 10.3bCHF 1.0b46.6x53.9x5.3x
Fri, 07 Jun 2024CHF 53.6bCHF 10.3bCHF 1.0b43.9x53.5x5.2x
Sun, 05 May 2024CHF 54.4bCHF 10.3bCHF 1.0b43.4x54.3x5.3x
Tue, 02 Apr 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Thu, 29 Feb 2024CHF 50.6bCHF 10.2bCHF 982.4m46.9x51.6x5x
Sat, 27 Jan 2024CHF 46.5bCHF 10.2bCHF 1.0b42.3x45.6x4.6x
Mon, 25 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Wed, 22 Nov 2023CHF 41.3bCHF 9.8bCHF 1.5b29.5x27.7x4.2x
Fri, 20 Oct 2023CHF 39.1bCHF 9.8bCHF 1.5b27.2x26.2x4x
Sun, 17 Sep 2023CHF 52.6bCHF 9.8bCHF 1.5b35.4x35.3x5.4x
Tue, 15 Aug 2023CHF 53.2bCHF 9.8bCHF 1.5b35.5x34.4x5.4x
Thu, 13 Jul 2023CHF 55.6bCHF 9.7bCHF 1.6b37.2x34x5.7x
Sat, 10 Jun 2023CHF 58.7bCHF 9.7bCHF 1.6b37x35.9x6.1x
Mon, 08 May 2023CHF 62.0bCHF 9.7bCHF 1.6b41.3x38x6.4x
Wed, 05 Apr 2023CHF 57.6bCHF 9.7bCHF 1.7b41.7x34.5x5.9x
Fri, 03 Mar 2023CHF 58.7bCHF 9.6bCHF 1.7b34.3x35.3x6.1x
Price to Earnings Ratio

35.3x


Total Market Cap: CHF 58.7bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 45.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.8x which is lower than its 3-year average PE of 45.9x.
  • The industry is trading close to its 3-year average PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 8.1% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.13%
Healthcare1.21%
Life Sciences-2.94%
Clinical Research and Equipment-2.94%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TECN Tecan GroupCHF 133.402.7%
+CHF 44.5m		-34.0%PE26.8x
XLS Xlife SciencesCHF 22.807.5%
+CHF 9.2m		21.0%PE4.3x
SKAN SKAN GroupCHF 51.400.6%
+CHF 6.7m		-33.3%PE71.4x

Latest News

BANB
CHF 56.15
Bachem Holding
7D
-11.6%
1Y
-4.1%
SFZN
CHF 79.00
Siegfried Holding
7D
-11.6%
1Y
-21.6%
TECN
CHF 133.40
Tecan Group
7D
2.7%
1Y
-34.0%

TECN: Recent Upgrade And CHF 205 Goal Will Support Higher Long Term P/E

Analysts have nudged their price targets on Tecan Group slightly lower, with moves such as Morgan Stanley trimming its target by CHF 5 and others, including Bernstein and Berenberg, adjusting their outlooks. These revisions have led to only marginal changes in modeled fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.
SKAN
CHF 51.40
SKAN Group
7D
0.6%
1Y
-33.3%

SKAN: Stable Assumptions And Higher Future P/E Will Support Upside Potential

Analysts have kept their CHF price target for SKAN Group effectively unchanged at around CHF 70.33, citing only marginal tweaks to the discount rate, revenue growth and profit margin assumptions, along with a slightly higher future P/E expectation. Valuation Changes Fair Value: CHF 70.33 remains unchanged, indicating no shift in the overall intrinsic value estimate.
LONN
CHF 520.60
Lonza Group
7D
-1.3%
1Y
-10.8%
PPGN
CHF 24.75
PolyPeptide Group
7D
-5.2%
1Y
10.7%

Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity

Catalysts About PolyPeptide Group PolyPeptide Group is a contract development and manufacturing partner focused on therapeutic peptides across development and commercial scales. What are the underlying business or industry changes driving this perspective?
XLS
CHF 22.80
Xlife Sciences
7D
7.5%
1Y
21.0%